Objectives

To determine the usefulness of hsa-miR-346, a potential biomarker enhancing the activity of non-tuberculous mycobacterial diseases, as a biomarker of tuberculosis activity.

Methods

We investigated whether hsa-miR-346 is secreted by human macrophages infected with Mycobacterium tuberculosis (M. tuberculosis) in an in vitro study. In addition, a cross-sectional study was conducted first to evaluate whether serum hsa-miR-346 is elevated in patients with tuberculosis compared with that in healthy individuals. Second, we conducted a retrospective study to evaluate whether anti-tuberculosis treatment reduces serum hsa-miR-346 levels.

Results

Log hsa-miR-346 levels were significantly elevated in the supernatant of human macrophages infected with M. tuberculosis in a dose-dependent manner. The mean serum log hsa-miR-346 levels were −15.48 (−15.76 to −15.21) in patients with tuberculosis and −16.12 (−16.29 to −15.95) in healthy volunteers, which significantly differed. In addition, hsa-miR-346 significantly decreased at 2 months from starting an anti-tuberculosis treatment.

Conclusions

We consider hsa-miR-346 as a potential biomarker enhancing the tuberculosis activity.

中文翻译：

---

增强结核病活性的潜在生物标志物 hsa-miR-346

目标

为了确定hsa -miR-346（一种增强非结核分枝杆菌疾病活性的潜在生物标志物）作为结核病活性的生物标志物的有用性。

方法

我们在体外研究中调查了hsa -miR-346 是否由感染结核分枝杆菌( M. tuberculosis )的人类巨噬细胞分泌。此外，首先进行了一项横断面研究，以评估与健康个体相比，结核病患者的血清hsa -miR-346 是否升高。其次，我们进行了一项回顾性研究，以评估抗结核治疗是否降低血清hsa -miR-346 水平。

结果

Log hsa -miR-346 水平在感染结核分枝杆菌的人巨噬细胞的上清液中以剂量依赖性方式显着升高。肺结核患者的平均血清 log hsa -miR-346 水平为 -15.48（-15.76 至 -15.21），健康志愿者为 -16.12（-16.29 至 -15.95），两者之间存在显着差异。此外，hsa -miR-346 在开始抗结核治疗 2 个月时显着下降。

结论

我们认为hsa -miR-346 是增强结核病活性的潜在生物标志物。